Susoctocog alfa in Hemorrhage: NCT04580407 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 16 October 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 2/3
Clinical phase
Completed
Recruitment status
not reported
Planned enrollment
2022-11-29
Primary-completion proxy
Executive view
NCT04580407 evaluates Susoctocog alfa in Hemorrhage. The disclosed sponsor is Takeda Pharmaceutical Co., Ltd., the design is Interventional, and the geographic footprint is Japan. The first listed primary endpoint is Percentage of Participants With Severe Bleeding Episodes Who Demonstrated Response to TAK-672 Therapy at 24 Hours After the Initiation of Treatment, assessed over 24 hours after the initial dose of TAK-672.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT04580407 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Hemorrhage landscape. Drug & Asset MCP drug_fetch was queried for Susoctocog alfa, while Company & Deal Intelligence MCP organization_fetch was queried for Takeda Pharmaceutical Co., Ltd..
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT04580407 | Susoctocog alfa | Phase 2/3 / Completed | Takeda Pharmaceutical Co., Ltd. | Japan | Percentage of Participants With Severe Bleeding Episodes Who Demonstrated Response to TAK-672 Therapy at 24 Hours After… 24 hours after the initial dose of TAK-672 | 2022-11-29 |
| NCT05441553 | VGB-R04 | Phase 1/2 / Unknown status | Shanghai Vitalgen Biopharma Co., Ltd. | China | Incidence of adverse events Baseline up to Week 52 | 2025-01-01 |
| NCT05421429 | Armocibart | Phase 2 / Completed | Suzhou Alphamab Co., Ltd. | China | Frequency and severity of treatment emergent adverse events(TEAEs) Day 1 up to Day 85 | 2024-01-17 |
| NCT05365217 | Nonacog beta pegol | Phase 3 / Completed | Novo Nordisk A/S | China | Haemostatic Effect of Nonacog Beta Pegol When Used for Treatment of Bleeding Episodes During on Demand and Prophylaxis… From start of treatment (week 0) until end of treatment (up to week 5… | 2024-04-11 |
| NCT05306418 | Denecimig | Phase 3 / Completed | Novo Nordisk A/S | United States, Japan, United Kingdom, Switzerland, Portugal, Spain, Russia, India, Canada, South Korea, Netherlands, China, Taiwan Province, Poland, South Africa, Italy, Israel, Lithuania, Germany | Number of treatment emergent adverse events From treatment initiation to follow up visit (week 0 to week 72) | 2024-11-13 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT04580407 is a Phase 2/3, completed study with not reported planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment.
The primary endpoint is “Percentage of Participants With Severe Bleeding Episodes Who Demonstrated Response to TAK-672 Therapy at 24 Hours After the Initiation of Treatment” over “24 hours after the initial dose of TAK-672.” The retrieved endpoint description is: Percentage of severe bleeding episodes with demonstrated response to TAK-672 therapy at 24 hours after the initiation of treatment was assessed by using a well-defined 4-point ordinal scale - A 'positive response' was defined as 'effective' (bleeding stopped with clinical control and FVIII:C levels of 50% or higher ) or 'partially effective' (bleeding reduced with clinical stabilization and FVIII:C levels of 20% or higher) control of bleeding, as determined by the investigator using a 4-point rating scale (effective - partially effective - poorly effective - not effective). 'Poorly effective' was defined as 'ble….
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of not reported should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
0 recent result records were selected as contextual evidence for Hemorrhage. These records do not establish direct evidence for NCT04580407 unless the registration number matches.
Indexed evidence status
No directly comparable result record was retrieved for this disease query. This is a monitoring gap, not evidence of absence.
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
Susoctocog alfa is indexed as Recombinant coagulation factor with F10 biology and a global stage of Approved. The asset profile lists Baxalta, Inc. as an originator or developer.
Takeda Pharmaceutical Co., Ltd. is indexed in an unreported country with the website http://www.takeda.com. Engages in the research, development, manufacturing and marketing of pharmaceutical products The record lists 243 development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Susoctocog alfa is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT04580407
Protocol source: https://clinicaltrials.gov/study/NCT04580407
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 16 October 2026.
Susoctocog alfa in Hemorrhage is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Percentage of Participants With Severe Bleeding Episodes Who Demonstrated Response to TAK-672 Therapy at 24 Hours After the Initiation of Treatment and 2022-11-29 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
